• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Allergan to acquire Kythera Biopharmaceuticals

Allergan to acquire Kythera Biopharmaceuticals

June 22, 2015
CenterWatch Staff

Allergan, a global pharmaceutical company, has agreed to acquire Kythera Biopharmaceuticals, a Westlake Village, Calif.-based biopharmaceutical company, in a cash and equity transaction valued at $75 per Kythera share, or approximately $2.1 billion, subject to the fulfillment of certain customary conditions.

The fixed-value transaction consideration will be payable 80% in cash and 20% in new AGN shares issued to Kythera shareholders. Allergan's 2015 earnings-per-share forecast provided on May 11 is unchanged as a result of the acquisition. The acquisition is expected to be breakeven in 2016 and accretive thereafter. The company remains committed to de-levering to below 3.5x debt to adjusted EBITDA by the end of the first quarter of 2016.

The acquisition of Kythera immediately enhances Allergan's global facial aesthetics portfolio with the addition of Kybella (deoxycholic acid) injection, the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, commonly referred to as double chin. Kybella was approved by the FDA on April 29. Kybella injection also is being developed for potential introduction into international markets; Kythera has submitted Kybella injection for regulatory approval in Switzerland, Canada and Australia, with other market applications to follow. The acquisition also will add Kythera’s development product setipiprant (KYTH-105), a novel compound for the prevention of male pattern baldness, as well as additional early-stage development candidates.

Brent Saunders, CEO and president of Allergan, said, "Kybella also is a pivotal entry point for expanding the use of facial aesthetic products in men, while Kythera’s setipiprant (hair-loss) development program can drive additional long-term value."

Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance—leading to an older and heavier look. Submental fullness can affect adults—both women and men—of all ages, weight and gender. Influenced by multiple factors including aging and genetics, submental fullness often is resistant to diet and exercise. According to a 2015 survey by the American Society for Dermatologic Surgery, 67% of consumers are bothered by submental fullness.

Kythera is executing a training-led launch in the U.S. supported by a training program designed to educate physicians and qualified injectors on the safe use of Kybella and its approved indication. Physician faculty education in the U.S. began in June. Kybella’s physician training programs will initiate in late summer. Qualified injectors in the U.S. will be able to purchase Kybella and treat their patients after they have been trained. 

Allergan's acquisition of Kythera is subject to approval by the shareholders of Kythera, expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and fulfillment of certain other customary conditions to closing. Pending such approvals and fulfillment of other conditions, Allergan currently anticipates closing the transaction in the third quarter of 2015.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing